0513 interline ecp EMB thurs 9am PT
BioCentury & Getty Images

Emerging Company Profile

Interline: correcting mutation-induced dysfunctional protein networks 

Emerging Company Profile: Interline launches from Foresite Labs with platform to identify and fix altered protein networks in cancer, inflammation

Foresite, Arch provide newly launched Interline with $92 million to develop small molecules to correct mutation-driven dysfunction of protein networks in cancer and inflammatory disease.

May 13, 2021 | 11:38 PM GMT

Interline has launched from Foresite Labs with $92 million in funding

Read the full 787 word article

How to gain access

Continue reading with a
two-week free trial.